Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12865317rdf:typepubmed:Citationlld:pubmed
pubmed-article:12865317lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C0010762lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C1171362lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C0014942lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C0597298lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C1515670lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C0311404lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:12865317lifeskim:mentionsumls-concept:C0205431lld:lifeskim
pubmed-article:12865317pubmed:issue8lld:pubmed
pubmed-article:12865317pubmed:dateCreated2003-7-16lld:pubmed
pubmed-article:12865317pubmed:abstractTextWe systematically characterized the oxidative metabolites of 17beta-estradiol and estrone formed by 15 human cytochrome P450 (CYP) isoforms. CYP1A1 had high activity for 17beta-estradiol 2-hydroxylation, followed by 15alpha-, 6alpha-, 4-, and 7alpha-hydroxylation. However, when estrone was the substrate, CYP1A1 formed more 4-hydroxyestrone than 15alpha- or 6alpha-hydroxyestrone, with 2-hydroxyestrone as the major metabolite. CYP1A2 had the highest activity for the 2-hydroxylation of both 17beta-estradiol and estrone, although it also had considerable activity for their 4-hydroxylation (9-13% of 2-hydroxylation). CYP1B1 mainly catalyzed the formation of catechol estrogens, with 4-hydroxyestrogens predominant. CYP2A6, 2B6, 2C8, 2C9, 2C19, and 2D6 each showed a varying degree of low catalytic activity for estrogen 2-hydroxylation, whereas CYP2C18 and CYP2E1 did not show any detectable estrogen-hydroxylating activity. CYP3A4 had strong activity for the formation of 2-hydroxyestradiol, followed by 4-hydroxyestradiol and an unknown polar metabolite, and small amounts of 16alpha- and 16beta-hydroxyestrogens were also formed. The ratio of 4- to 2-hydroxylation of 17beta-estradiol or estrone with CYP3A4 was 0.22 or 0.51, respectively. CYP3A5 had similar catalytic activity for the formation of 2- and 4- hydroxyestrogens. Notably, CYP3A5 had an unusually high ratio of 4- to 2-hydroxylation of 17beta-estradiol or estrone (0.53 or 1.26, respectively). CYP3A4 and 3A5 also catalyzed the formation of nonpolar estrogen metabolite peaks (chromatographically less polar than estrone). CYP3A7 had a distinct catalytic activity for the 16alpha-hydroxylation of estrone, but not 17beta-estradiol. CYP4A11 had little catalytic activity for the metabolism of 17beta-estradiol and estrone. In conclusion, many human CYP isoforms are involved in the oxidative metabolism of 17beta-estradiol and estrone, with a varying degree of catalytic activity and distinct regioselectivity.lld:pubmed
pubmed-article:12865317pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:languageenglld:pubmed
pubmed-article:12865317pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12865317pubmed:statusMEDLINElld:pubmed
pubmed-article:12865317pubmed:monthAuglld:pubmed
pubmed-article:12865317pubmed:issn0013-7227lld:pubmed
pubmed-article:12865317pubmed:authorpubmed-author:LeeAnthony...lld:pubmed
pubmed-article:12865317pubmed:authorpubmed-author:ConneyAllan...lld:pubmed
pubmed-article:12865317pubmed:authorpubmed-author:ZhuBao TingBTlld:pubmed
pubmed-article:12865317pubmed:authorpubmed-author:CaiMay...lld:pubmed
pubmed-article:12865317pubmed:authorpubmed-author:ThomasPaul...lld:pubmed
pubmed-article:12865317pubmed:issnTypePrintlld:pubmed
pubmed-article:12865317pubmed:volume144lld:pubmed
pubmed-article:12865317pubmed:ownerNLMlld:pubmed
pubmed-article:12865317pubmed:authorsCompleteYlld:pubmed
pubmed-article:12865317pubmed:pagination3382-98lld:pubmed
pubmed-article:12865317pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:meshHeadingpubmed-meshheading:12865317...lld:pubmed
pubmed-article:12865317pubmed:year2003lld:pubmed
pubmed-article:12865317pubmed:articleTitleCharacterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.lld:pubmed
pubmed-article:12865317pubmed:affiliationDepartment of Basic Pharmaceutical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina 29208, USA.lld:pubmed
pubmed-article:12865317pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12865317pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12865317pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
literatureCitation:4512_128...literatureCitation:pubmedpubmed-article:12865317lld:drugbank
literatureCitation:4200_128...literatureCitation:pubmedpubmed-article:12865317lld:drugbank
entrez-gene:1551entrezgene:pubmedpubmed-article:12865317lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12865317lld:pubmed